Joseph Yeargain, DPM
Foot & Ankle Surgery · Dallas, TXNPI 1023271202
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (59.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Arthrex at 42.8% of the total. Reporting peaked in 2022 at $3,365 and has fallen 99.6% since, to $14 in 2025.
Across 35 payments — averaging $191.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$3K
- Pylant Medical$2K
- Paragon 28, Inc.$831
- Integra Lifesciences Corporation$258
- Kerecis Limited$173
- Bone Support Inc.$150
- plus $418 from 5 others
What the payments were for
- Travel & lodging$78112%
- Food & beverage$1,90428%
- Education$4,01860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 13 | $2,870 |
| Pylant Medical | 9 | $2,003 |
| Paragon 28, Inc. | 3 | $831 |
| Integra Lifesciences Corporation | 1 | $258 |
| Kerecis Limited | 1 | $173 |
| Bone Support Inc. | 1 | $150 |
| Orthofix Medical, Inc. | 2 | $128 |
| Bioventus LLC | 2 | $118 |
| Otsuka America Pharmaceutical, Inc. | 1 | $116 |
| Stryker | 1 | $43 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CYTAL$517
- Kerecis Omega3 Wound$173
- Kerecis Omega3 Surgibind$173
- Kerecis Omega3 GraftGuide$173
- Kerecis Omega3 SurgiClose$173
- CERAMENTBONE VOID FILLER$150
- CERAMENT G$150
- Physio-Stim$123
- REXULTI$116
- Exogen$104
How this compares
$6,703 in reported general payments places this provider in the 65th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Terbinafine Hcl | 160 | $1,235 |
| Itraconazole | 11 | $320 |
| Cephalexin | 32 | $160 |
| Meloxicam | 44 | $89 |
| Methylprednisolone | 18 | $88 |
| Hydrocortisone | 11 | $70 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Dallas
- Eugene CurryDallas$3.1M
- Paul KimDallas$928K
- John EarlyDallas$553K
- Dane WukichDallas$189K
- Charles CookDallas$92K
- Trapper LalliDallas$74K
- Veerabhadra ReddyDallas$59K
- John NoackDallas$49K
- William McGarveyKaty$3.5M
- Graham HamiltonEdinburg$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.